RxDoctor Payments Data

Christopher Paul

Pain Medicine · Birmingham, ALNPI 1487940656

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (30.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. MML US, Inc. accounts for 64.7% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $29,948, 9.7 times the $3,103 reported in 2019. Among pain medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,649in general payments, 2019–2025

Across 301 payments — averaging $211.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MML US, Inc.$41K
  • Abbott$14K
  • Saluda Medical Americas, Inc.$4K
  • Stryker$953
  • Nevro Corp.$814
  • Medtronic$510
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$18,09428%
  • Speaking & faculty fees$14,52523%
  • Travel & lodging$19,35730%
  • Food & beverage$11,67318%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,649 in reported general payments places this provider in the 95th percentile of 77 pain medicine providers in Alabama.

See all pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$82,021
Medicare patients
277
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl22$13,367
Buprenorphine68$11,618
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen218$4,535
Gabapentin208$3,246
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen116$2,951
Pregabalin71$2,886
Oxycodone Hcl55$541
Morphine Sulfate17$371
Tramadol Hcl30$218
Cephalexin18$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$31$13,36722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 pain medicine providers in Alabama.

Other pain medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →